-
Recently, two more domestically-made innovative drugs have been approved for marketing!
Time of Update: 2021-12-03
They are aoribatinib tablets for the treatment of resistance to any tyrosine kinase inhibitor; innovative PD-L1 antibody drugs, suitable for unresectable or metastatic microsatellite highly unstable (MSI-H) or mismatch repair Envolimab injection for the treatment of adult patients with advanced solid tumors with genetic defects (dMMR) .
-
National procurement of insulin is approaching, and such companies will escort product quality
Time of Update: 2021-12-03
For example, in the face of national procurement, relevant pharmaceutical companies need to think about how to transform and upgrade, and use policies to reduce costs, control prices, improve product quality, and expand market share .
-
Innovative pharmaceutical companies have launched more than 30 transactions during the year
Time of Update: 2021-12-03
On August 8, 2021, Rongchang Biologics reached a cooperation agreement with Seattle Genes to develop and commercialize its new ADC drug, vedicitumumab.
The drug has received conditional marketing approval in China for the treatment of locally advanced metastatic gastric cancer .
-
6 pharmacies will be available soon
Time of Update: 2021-12-03
It is worth mentioning that this wave of chain pharmacies getting listed on the market represents two trends: one professional development (Sipai Health, Yuanxin Technology, Dajia Weikang), focusing on the new pattern of prescription outflow; and an innovative development (Dingdong Kuaiyao , Quanyuantang), focusing on the new trend of Internet medicine .
-
Right Biao Yangtze River!
Time of Update: 2021-12-03
com database A few days ago, the CDE official website showed that Sichuan Guorui Pharmaceutical's dexmedetomidine hydrochloride sodium chloride injection and dexmedetomidine hydrochloride injection have been accepted as imitation 3 types of listing applications .
-
Insulin enters the sixth batch of drug collection, diabetic patients may bid farewell to the "sweet burden"
Time of Update: 2021-12-03
In addition, an analyst in the pharmaceutical industry said that due to the large base of diabetes patients and insulin is an important drug for diabetes treatment, which involves people’s livelihood issues, the country has an incentive to reduce the cost of medication.
-
New crown Nu strain appeared in the arena
Time of Update: 2021-12-03
Drug source analysisDrug source analysisViruses mutate all the time, so the emergence of new strains is always happening .
This not only makes the control of the new crown in low-income countries stretched, but also increases the chance that Nu, a highly variable strain, will inevitably spread globally .
-
The results of insulin production in China are released!
Time of Update: 2021-12-03
This collection covers the second- and third-generation insulins commonly used in clinical practice, involving 11 companies and 16 generic varieties, and the average price of the products to be selected is reduced by 48 %, it is estimated that 9 billion yuan can be saved every year, which will bring good news to over 140 million diabetic patients in China .
-
2022 The 9th International Biological Fermentation Products and Technology Equipment Exhibition (Jinan)
Time of Update: 2021-12-03
March 30-April 1, 2022 | Shandong International Convention and Exhibition Center (No. 1 Rizhao Road, Jinan) 4 exhibition linkage, 600+ brands, sharing 36000+ buyers, 40000㎡ exhibition area Supporting
-
Medical representatives face new challenges!
Time of Update: 2021-12-03
From 2022 to 2024, the task of reforming the DRG/DIP payment method will be fully completed, and the high-quality development of medical insurance will be promoted .
-
Pharmaceutical equipment is continuously helping the Chinese medicine industry to accelerate its development in the direction of modernization
Time of Update: 2021-12-03
In general, it is the responsibility of pharmaceutical equipment companies to use modern science and technology to promote the modernization of Chinese medicine and to open up new paths for the inheritance, innovation and development of Chinese medicine.
-
The pharmaceutical equipment industry has a strong momentum of development, and companies should keep pace with the times and accelerate innovation
Time of Update: 2021-12-03
In general, in the context of many favorable pharmaceutical policies and the continuous development of science and technology, the industry expects that China's pharmaceutical equipment industry will usher in more opportunities, but at the same time, the competition of related enterprises will also reach new heights.
-
Section 6!
Time of Update: 2021-12-03
WenSunshineOn November 26, the official website of the Food and Drug Administration showed that Bevacizumab biosimilar (MIL60) of Betta Pharmaceuticals was approved for marketing for the treatment of advanced, metastatic or recurrent non-small cell lung cancer and metastatic colorectal Cancer patients .
-
The prospects for the development of Chinese medicine overseas markets are considerable, and these bottlenecks still need to be broken
Time of Update: 2021-12-03
Therefore, if pharmaceutical companies want to better guarantee drug safety, they must use technological innovation to develop modern Chinese medicine scientific research and industrial production technology to continuously promote the development of the Chinese medicine industry in a high-quality direction .
-
NMPA approves the listing of Xuanqijian Bone Tablets, Qizhi Yishen Capsules and Kunxinning Granules
Time of Update: 2021-12-03
Recently, the National Medical Products Administration approved the marketing registration application for three innovative Chinese medicines: Xuanqijiangu Pian, Qizhi Yishen Capsule and Kunxinning Granules .
Recently, the National Medical Products Administration approved the marketing registration application for three innovative Chinese medicines: Xuanqijiangu Pian, Qizhi Yishen Capsule and Kunxinning Granules .
-
How will the pharmaceutical equipment market be interpreted at the end of the year, and how will it be laid out in the next phase?
Time of Update: 2021-12-03
It is expected that the market for pharmaceutical equipment at the end of the year will still be worth seeing in the context of the continued prosperity of the innovative medicine and CXO industries .
-
Shi Fuxin is the head of the new drug discovery and preclinical research of Ruizheng and the general manager of the U.S. subsidiary
Time of Update: 2021-12-03
Shi Fuxin will lead the research team to be responsible for innovative technology development, new target confirmation and product pipeline layout, and to quickly advance the product projects developed in the early stage into the clinic .
-
The overall growth rate of the chemical preparation industry has improved, and focus on this type of enterprise
Time of Update: 2021-12-03
In recent years, with China's significant increase in public medical investment, as well as the steady economic growth, the improvement of people's living standards, and the enhancement of health awareness, the domestic chemical pharmaceutical preparation market has maintained rapid growth .
-
As the market continues to expand, the pharmaceutical machinery industry will accelerate development in these directions
Time of Update: 2021-12-03
In this regard, the industry believes that under this trend, through the continuous development and innovation of pharmaceutical machinery companies in the future, domestic pharmaceutical equipment companies will gradually become a segment of China's high-end manufacturing, and their performance will continue to grow; in addition, the industry will also The cyclical attribute is gradually faded to usher in long-term growth .
-
More than 400 young doctors focus on cutting-edge technologies for precision medicine exchanges
Time of Update: 2021-12-02
" Liu Liang, academician of the Chinese Academy of Engineering and Honorary President of Macau University of Science and Technology, shared and introduced cutting-edge technologies and industries in Chinese medicine and chronic disease management to the young doctors present .
